Open AccessMaintenance Therapy Improves AML Outcomes Regardless of MRD Status or Consolidation Cycles
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13649
Subject(s) - medicine , azacitidine , minimal residual disease , myeloid leukemia , maintenance therapy , oncology , clinical trial , disease , intensive care medicine , leukemia , chemotherapy , biochemistry , gene expression , chemistry , dna methylation , gene
New data from the phase III QUAZAR AML‐001 trial confirm the benefits of maintenance therapy with oral azacitidine in acute myeloid leukemia regardless of patients' minimal residual disease status or the number of consolidation cycles prior to study enrollment.